Logo image of CINC

CINCOR PHARMA INC (CINC) Stock Fundamental Analysis

USA - NASDAQ:CINC - US17240Y1091 - Common Stock

29.06 USD
-0.14 (-0.48%)
Last: 2/23/2023, 8:00:00 PM
29.25 USD
+0.19 (+0.65%)
After Hours: 2/23/2023, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, CINC scores 3 out of 10 in our fundamental rating. CINC was compared to 192 industry peers in the Pharmaceuticals industry. CINC has a great financial health rating, but its profitability evaluates not so good. CINC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CINC had negative earnings in the past year.
In the past year CINC has reported a negative cash flow from operations.
CINC Yearly Net Income VS EBIT VS OCF VS FCFCINC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -10M -20M -30M -40M -50M

1.2 Ratios

The profitability ratios for CINC are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CINC Yearly ROA, ROE, ROICCINC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CINC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CINC Yearly Profit, Operating, Gross MarginsCINC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, CINC has about the same amount of shares outstanding.
There is no outstanding debt for CINC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CINC Yearly Shares OutstandingCINC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 10M 20M 30M
CINC Yearly Total Debt VS Total AssetsCINC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 50M 100M

2.2 Solvency

An Altman-Z score of 75.25 indicates that CINC is not in any danger for bankruptcy at the moment.
CINC's Altman-Z score of 75.25 is amongst the best of the industry. CINC outperforms 98.65% of its industry peers.
CINC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 75.25
ROIC/WACCN/A
WACCN/A
CINC Yearly LT Debt VS Equity VS FCFCINC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M 100M

2.3 Liquidity

CINC has a Current Ratio of 51.96. This indicates that CINC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CINC (51.96) is better than 99.55% of its industry peers.
CINC has a Quick Ratio of 51.96. This indicates that CINC is financially healthy and has no problem in meeting its short term obligations.
CINC's Quick ratio of 51.96 is amongst the best of the industry. CINC outperforms 99.55% of its industry peers.
Industry RankSector Rank
Current Ratio 51.96
Quick Ratio 51.96
CINC Yearly Current Assets VS Current LiabilitesCINC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 50M 100M

More info and screens

1

3. Growth

3.1 Past

CINC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.88%.
EPS 1Y (TTM)-125.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.98% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y72.63%
EPS Next 2Y29.7%
EPS Next 3Y17.87%
EPS Next 5Y24.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CINC Yearly Revenue VS EstimatesCINC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
CINC Yearly EPS VS EstimatesCINC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CINC. In the last year negative earnings were reported.
Also next year CINC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CINC Price Earnings VS Forward Price EarningsCINC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CINC Per share dataCINC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 -15

4.3 Compensation for Growth

CINC's earnings are expected to grow with 17.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.7%
EPS Next 3Y17.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CINC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CINCOR PHARMA INC

NASDAQ:CINC (2/23/2023, 8:00:00 PM)

After market: 29.25 +0.19 (+0.65%)

29.06

-0.14 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2022-11-03/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.29%
Ins Owner Change0%
Market Cap1.27B
Revenue(TTM)N/A
Net Income(TTM)-88093300
Analysts78.33
Price Target39.78 (36.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.35%
Min EPS beat(2)-9.15%
Max EPS beat(2)17.84%
EPS beat(4)2
Avg EPS beat(4)-219.2%
Min EPS beat(4)-887.3%
Max EPS beat(4)17.84%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.99%
EPS NY rev (1m)0%
EPS NY rev (3m)6.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.45
P/tB 2.45
EV/EBITDA N/A
EPS(TTM)-17.28
EYN/A
EPS(NY)-2.55
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0
BVpS11.86
TBVpS11.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 51.96
Quick Ratio 51.96
Altman-Z 75.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
EPS Next Y72.63%
EPS Next 2Y29.7%
EPS Next 3Y17.87%
EPS Next 5Y24.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.84%
EBIT Next 3Y-8.54%
EBIT Next 5YN/A
FCF growth 1Y-77.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-77.32%
OCF growth 3YN/A
OCF growth 5YN/A

CINCOR PHARMA INC / CINC FAQ

Can you provide the ChartMill fundamental rating for CINCOR PHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to CINC.


Can you provide the valuation status for CINCOR PHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to CINCOR PHARMA INC (CINC). This can be considered as Overvalued.


Can you provide the profitability details for CINCOR PHARMA INC?

CINCOR PHARMA INC (CINC) has a profitability rating of 1 / 10.


How financially healthy is CINCOR PHARMA INC?

The financial health rating of CINCOR PHARMA INC (CINC) is 8 / 10.